Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of TRC101 in Subjects With Chronic Kidney Disease and Metabolic Acidosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Estimated glomerular filtration rate (eGFR) of 20 to \<60 mL/min/1.73m2~* Serum bicarbonate level of 12 to 20 mEq/L~Exclusion Criteria:~* Any level of low serum bicarbonate that, in the opinion of the Investigator, requires emergency intervention.~* Severe comorbid conditions other than chronic kidney disease.~* Chronic obstructive pulmonary disease.~* Anticipated changes in doses of any of the following drugs or drug classes: diuretics, non-ophthalmic carbonic anhydrase inhibitors, oral diabetes drugs, antihypertensive drugs, antacids, H2-blockers, or proton pump inhibitors.~* Excluded drugs or drug classes: insulin, non-daily or as needed diuretics, herbal products, dietary supplements, multivitamins, naturopathic remedies, sodium bicarbonate, potassium citrate, sodium citrate or other alkali therapy, non-steroidal anti-inflammatory drugs (NSAIDs), fiber supplements, laxatives, calcium and magnesium supplements, or electrolyte binders and other binder drugs.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo-BID (Type: PLACEBO_COMPARATOR): Administered twice daily (BID) for 14 days
- TRC101 (1.5g BID) (Type: EXPERIMENTAL): Administered twice daily (BID) for 14 days
- TRC101 (3g BID) (Type: EXPERIMENTAL): Administered twice daily (BID) for 14 days
- TRC101 (4.5g BID) (Type: EXPERIMENTAL): Administered twice daily (BID) for 14 days
- TRC101 (6g QD) (Type: EXPERIMENTAL): Administered once daily (QD) for 14 days
- Placebo-QD (Type: PLACEBO_COMPARATOR): Administered once daily (QD) for 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).